Business Week in Review
Talbots eyes closing J. Jill's headquarters
Two years after Talbots Inc. acquired the J. Jill chain, the apparel retailer is looking to shut down J. Jill's posh Quincy headquarters in Batterymarch Park and relocate the roughly 200 employees there to the Talbots headquarters in Hingham.
Talbots CEO Trudy Sullivan is in the midst of a cost-cutting effort aimed at wringing about $100 million out of the company's budget.
There's more than one duck tour in town
The amphibious tour battles will continue this summer in Boston as a federal appeals court judge ruled that upstart Super Duck Tours could use the phrase “duck tour” over the objections of longtime incumbent Boston Duck Tours.
The ruling overturns a lower court judge's decision that using the “duck tour” phrase and a similar logo would confuse tourists.
Casual Male expands by buying competitor
While many retailers are retrenching in this weak economy, Casual Male Retail Group has figured out a way to expand by buying seven stores from a Utah-based big-and-tall men's apparel chain.
The deal with Dahle's Big & Tall will bring Casual Male into three new states - Montana, Idaho and Utah - and bring the total number of states where the Canton company has stores to 47. But several other Dahle's stores that compete with Casual Male will close after Casual Male opted not to buy them.
Patrick signs $1B life sciences legislation
Gov. Deval Patrick on Monday signed a bill that would spread as much as $1 billion among the life sciences industries over 10 years just in time to jet off to San Diego for the annual Biotechnology Industry Organization conference.
There, Bay State leaders such as Patrick, House Speaker Sal DiMasi and Senate President Therese Murray were busy this week trying to promote the state to the biotech firms in attendance.
Icahn slate fails, in truce with Biogen Idec
Carl Icahn was forced to agree to a truce of sorts with the management of Biogen Idec after a failed effort to get his slate of dissidents elected to Biogen's board.
Icahn, a major Biogen investor, had previously tried to promote a potential sale of the Cambridge biotech company to a larger drug company, but Biogen said it wasn't able to find a viable offer.
The Patriot Ledger